RxDoctor Payments Data

Arsian Kahloon, MD

Gastroenterology · Chattanooga, TNNPI 1801025440

Payments from drug & device makers

$6,522in general payments, 2019–2025

Across 346 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$689
  • Gilead$365
  • Takeda Pharmaceuticals U.S.A., Inc.$357
  • Pfizer$283
  • Endogastric Solutions, Inc$282
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,40898%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,522 in reported general payments places this provider in the 65th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$61,252
Medicare patients
299
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab26$263,829
CreonLipase/Protease/Amylase12$23,450
LinzessLinaclotide29$19,476
Dexlansoprazole DrDexlansoprazole14$5,388
Lubiprostone21$2,886
Mesalamine18$2,214
Pantoprazole Sodium93$1,583
CholestyramineCholestyramine (With Sugar)16$1,449
Omeprazole39$670
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates11$604
Sucralfate12$482
Fluconazole15$253
Ondansetron OdtOndansetron11$189
Ondansetron Hcl17$186
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl14$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,975$42,92641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →